Agomelatine and Ramelteon prevent SARS-CoV-2 entry in the brain thereby reducing virus-induced damage of small cerebral vessels immune cell infiltration and brain inflammation

Funny, I didn't hear anyone, Tony, Rochelle, Collins, FDA, CDC, NIH anyone let on about this "science". https://t.co/Sy5oUaZ47N pic.twitter.com/Oq8qYadIBw

— DCGreenZone1 (@DCGreenZone) September 2, 2022

Agomelatine and ramelteon prevent SARS-CoV-2 entry in the brain thereby reducing virus-induced damage of small cerebral vessels immune cell infiltration and brain inflammation molecular modeling analysis complemented by experimental studies in cells show that SARS-CoV-2 entry into endothelial cells is prevented by melatonin binding to allosteric-binding site on human Angiotensin converting enzyme to ACE 2 that's interfering with ACE 2 function as an entry receptor for SARS-CoV-2 are findings open new perspectives for the repurposing of melatonin generic drugs and it's clinically used analogs in the prevention of brain infection by SARS-CoV-2 and Covid-19 related long-term neurological symptoms.